Table 2.
Response Parameters | N (%) | Response Parameters | N (%) |
---|---|---|---|
Neoadjuvant Therapy followed by breast operation and ALND | 341 (95.8%) | Breast Cancer Subtype | pCR |
pCR (ypT0/Tis and ypN0) | 106 (31.1%) | • HR+ Luminal A-like | 8 (15.4%) |
Pathological Tumor Stage | 356 | • HR+ Luminal B-like | 42 (25.0%) |
ypT0 | 125 (35.1%) | • HR+/HER2+ | 8 (30.8%) |
ypTis | 16 (4.5%) | • HR−/HER2+ | 10 (40.0%) |
ypT0/Tis | 141 (39.6%) | • Triple Negative | 25 (41.0%) |
ypT1 | 144 (40.4%) | • Unknown | 15 (62.5%) |
ypT2 | 52 (14.6%) | Response to Neoadjuvant Therapy | |
ypT3 | 6 (1.7%) | Any Primary Tumor Downstaging | 328 (92.1%) |
ypT4 | 13 (3.7%) | cN0 to ypN0 | 137 (40.2%) |
Pathological Nodal Stage | 341 | cN+ to ypN0 | 99 (29.0%) |
ypN0 | 236 (69.2%) | cN0 to ypN+ | 34 (10.0%) |
ypN1 | 57 (16.7%) | cN+ to ypN+ | 71 (20.8%) |
ypN2 | 32 (9.4%) | Mean T-Size Reduction [mm] | 45.4 |
ypN3 | 16 (4.7%) | Mean Residual Tumor Volume [%] | 13.0 |
Axillary Lymph Node Dissection | Median Residual Tumor Volume [%] | 0.2 | |
Mean Number of dissected Nodes | 19 | ||
Mean Number of + Nodes | 7 |